Pre-Open Stock Movers 02/04: (MXWL) (ULTI) (EOLS) Higher; (MGNX) (MTCH) (PEGI) Lower (more...)
- Dow ends at record high, Nasdaq falls as tech slides
- Trump's Facebook (FB) Ban Upheld, Oversight Board Asks Company to Come Up With a 'Proportionate Response' Going Forward
- PayPal (PYPL) Tops Q1 EPS by 21c, Offers Q2 and FY Guidance
- Peloton (PTON) Plunges After Recalling All Treadmills, Analyst Says Will Negatively Impact Broader Tread Rollout
- T-Mobile (TMUS) Gains After Topping Q1 Consensus as 5G Story Accelerates, 'More to Come' Says Analyst
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Today's Pre-Open Movers
Maxwell Technologies, Inc. (Nasdaq: MXWL) 52% HIGHER; announced it has entered into a definitive agreement to be acquired by Tesla, Inc. (Nasdaq: TSLA). Tesla will commence an all stock exchange offer for all the issued and outstanding shares of the Company, after which the Company will be merged with a Tesla subsidiary and become a wholly owned subsidiary of Tesla. The Offer will value each share of Maxwell common stock at $4.75 per share.
Ultimate Software (Nasdaq: ULTI) 19.4% HIGHER; entered into a definitive merger agreement to be acquired by an investor group led by Hellman & Friedman (H&F), a leading private equity investment firm, in an all-cash transaction for $331.50 per share in cash representing an aggregate value of approximately $11 billion after which Ultimate Software (Ultimate) will operate as a privately held company.
Evolus, Inc. (NASDAQ: EOLS) 13.8% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has approved its lead product, Jeuveau, for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adults.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) 9.2% HIGHER; argenx (NASDAQ: ARGX) and Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced a global collaboration and license agreement that enables use by argenx of Halozyme's ENHANZE® drug delivery technology to develop multiple subcutaneous product formulations for current or future argenx product candidates. The agreement provides argenx exclusive access to ENHANZE® for any product targeting the human neonatal Fc receptor FcRn, including argenx's lead asset efgartigimod (ARGX-113) and up to two additional targets, potentially shortening drug administration time, reducing healthcare practitioner time, and offering additional flexibility and convenience for patients.
MacroGenics (NASDAQ: MGNX) 6.7% LOWER; Citi downgraded from Neutral to Sell with a price target of $10.00 (from $22.00).
Match Group (NASDAQ: MTCH) 5.7% LOWER; Goldman Sachs initiates coverage with a Sell rating and a price target of $45.00.
Papa Johns International, Inc. (NASDAQ: PZZA) 5.6% HIGHER; announced that it has entered into a securities purchase agreement with Starboard Value LP pursuant to which Starboard is making a $200 million strategic investment in the Company with the option to make an additional $50 million investment through March 29, 2019, as described below. In connection with the investment, the Papa Johns Board of Directors is expanding to include two new independent directors, including Jeffrey C. Smith, Chief Executive Officer of Starboard, who has been appointed Chairman of the Papa Johns Board, and Anthony M. Sanfilippo, former Chairman and Chief Executive Officer of Pinnacle Entertainment, Inc.
Intercept Pharmaceuticals (NASDAQ: ICPT) 3.8% HIGHER; Raymond James upgraded from Outperform to Strong Buy with a price target of $184.00 (from $125.00).
JinkoSolar Holding Co., Ltd. (NYSE: JKS) 3.6% HIGHER; Roth Capital upgraded from Neutral to Buy and initiated a price target of $20 based on a 6.7 multiple of 2019 Earnings.
Alexion Pharma (NASDAQ: ALXN) 2.7% HIGHER; reported Q4 EPS of $2.14, $0.32 better than the analyst estimate of $1.82. Revenue for the quarter came in at $1.13 billion versus the consensus estimate of $1.06 billion. Alexion Pharma sees FY2019 EPS of $9.10-$9.30, versus the consensus of $8.73. Alexion Pharma sees FY2019 revenue of $4.625-4.7 billion, versus the consensus of $4.75 billion.
Yelp (NYSE: YELP) 2.5% HIGHER; Goldman Sachs initiates coverage on with a Buy rating and a price target of $42.00.
Pattern Energy Group (NASDAQ: PEGI) 1.6% LOWER; Macquarie downgraded from Neutral to Underperform with a price target of $18.50 (from $19.50).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Equinox Said to Discuss Going Public Via Social Capital SPAC (IPOD) (IPOF) - Bloomberg
- Sun Life Financial (SLF) Tops Q1 EPS by 56c
- UPDATE: Nuance Communications (NUAN) proxy suggests Amazon (AMZN) was interested - CNBC's Faber
Create E-mail Alert Related CategoriesSpecial Reports
Related EntitiesGoldman Sachs, Citi, Raymond James, Roth Capital, Hellman & Friedman LLC, Tesla, Earnings, Pre-Open Losers, Pre-Open Winners, Definitive Agreement, Starboard Value, Pre Market Movers, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!